Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Other factors contributing to leadership in the region include increased awareness about the co-morbid diseases associated with obesity, greater physician involvement, vigorous scientific research, and pharmaceutical investment in oral GLP-1 drugs, incretin-based, and multi-agonist drugs
doi: 10.1172/JCI112855 25 OrskovCHolstJJPoulsenSSKirkegaardP
Heightened scrutiny
Genetic predisposition testing may help provide context for individual metabolic profiles and support more targeted conversations between patients and primary care providers about whether GLP-1 aligns with baseline physiology and weight loss history
